Physician Practice M&A Multiples: 2026 Data
Physician practice M&A activity in the U.S. remains strong in 2026, despite elevated interest rates and the continued normalization from the 2021–2022 peaks. Private equity and strategic consolidators remain active, particularly in high-growth specialties where scale and ancillaries create significant value. Global healthcare private equity delivered a record-breaking performance in 2025, with disclosed deal value exceeding an estimated $191 billion and surpassing the previous high set in 2021.1
For physician-owners, understanding current valuation multiples is essential not only for timing a potential sale but also for benchmarking unsolicited offers, partner buyouts, or decisions regarding recapitalization. Multiples serve as a financial shorthand for how investors perceive the practice’s stability, scalability, and reimbursement strength. Even a single turn in multiple can translate into millions of dollars in transaction value.
While aggregate multiples have eased from the highs of 2021–2022, competition for well-run specialty groups continues to drive double-digit pricing across key segments. Practices that demonstrate growth potential, diversified payor mix, and advanced operational infrastructure consistently attract premium valuations. Buyers are more selective in 2026 than during the pandemic-era deal frenzy, placing greater emphasis on profitability, near-term revenue synergies, and demonstrated sustainability.2
Average EV/EBITDA Multiples by Specialty
Platform investments (initial entries into a specialty) command premium multiples, while add-on acquisitions of smaller groups trade at mid- to high-single-digit levels.
| Specialty | Platform Transactions (EV/EBITDA) | Add-On Transactions (EV/EBITDA) | Notes |
|---|---|---|---|
| Primary Care (Family/Internal Medicine, Pediatrics) | 8×–12× | 3×–6× | Scaled, value-based platforms can reach low-teens multiples. |
| Cardiology | 12×–15× | 8×–12× | Scarcity of independent groups drives sustained premiums. |
| Orthopedics & Sports Medicine | 9×–13× | 6×–9× | ASC and imaging ancillaries lift platform valuations. |
| Gastroenterology (GI) | 10×–14× | 7×–9× | Endoscopy and ASC ownership materially raise multiples. |
| Ophthalmology (incl. Retina) | 14×–20× | 7×–11× | Public-company RCA transaction underscores high-teens retina platform comps; add-on ranges widen with ASC/clinic density. |
| Ob/Gyn / Women’s Health | 10×–14× | 5×–8× | Sector remains an active PE focus; some multiple compression is observed from prior peaks. |
| Plastic Surgery & Aesthetics | 8×–12× | 4×–8× | Smaller, single-site aesthetics trade low- to mid-single digits; multi-site platforms can reach high-single to low-double digits. |
| Oncology / Urology | 14×–19× | 8×–12× | OneOncology deal includes a 19× EBITDA put/call; urology shows high PE penetration and steady add-on cadence. |
*These ranges reflect consensus data from 2024–2025 transactions compiled by Levin Associates and Pitchbook, supported by their respective deal experience. Methodology triangulates these benchmarks with recent high-signal transactions—most notably Cencora’s acquisition of Retina Consultants of America (retina MSO) and TPG/AmerisourceBergen’s OneOncology deal, which included a 19× EBITDA put-call. Broader sector context for women’s health, urology, and aesthetics is drawn from specialty white papers and market reports. Actual pricing continues to vary by scale, ancillaries, payor mix, regional density, and growth profile.
Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Specialty-by-Specialty Trends
Across U.S. physician practice M&A, valuation performance continues to vary significantly by specialty. Private equity and strategic buyers target subsectors differently based on procedural economics, scalability, and supply of independent groups.
Current specialty valuation highlights include:
Cardiology: Among the most sought-after segments, driven by the limited supply of independent groups and favorable procedural margins. Platform transactions can achieve mid-teens EBITDA multiples, supported by diagnostic testing revenue and outpatient cath lab expansion.3
Ophthalmology: Many private equity platforms compete for remaining high-quality, independent practices. Significant platform trades have injected new momentum into the retina and cataract surgery sub-segments.
Women’s Health: Viewed as a stable area for investment with many growth avenues (e.g., fertility, behavioral health), though some multiple compression has occurred relative to 2022–2023 peaks.
Plastic Surgery and Aesthetics: Experiencing high deal volume and competition, especially for platform assets. Investors are attracted to the cash-pay model and increasing demand for aesthetic services.
Oncology/Urology: Heavy drug utilization has drawn interest and capital from upmarket companies seeking integration. OneOncology remains a benchmark transaction in this space.
Gastroenterology: Sustained high demand for outpatient endoscopy and ancillary services has preserved strong cash flow profiles and premium valuations.
Orthopedics: Steady growth as surgical migration to ambulatory surgery centers (ASCs) accelerates, and musculoskeletal demand rises with an aging population. In October 2025, Hospital for Special Surgery and General Atlantic announced a joint venture to launch independently operated ambulatory surgical centers nationally, underscoring this trend.4
Primary Care: Once modestly valued, now seeing renewed investor interest via value-based and capitated care models. Practices demonstrating success in Medicare Advantage and ACO frameworks may reach double-digit multiples comparable to specialty peers.
Dermatology and Dentistry: Previously high-growth sectors experiencing modest multiple compression after several consolidation waves, as investors emphasize operational integration and margin optimization. In 2025, dermatology and dental care ranked among the top two PE-backed outpatient sectors by deal count.4
Pediatrics: One of the fastest-growing PE investment targets in 2026, with private equity investments in pediatric outpatient care tripling year-over-year in 2025. Specialty pediatric practices attract interest driven by demographic trends and practice fragmentation.4
Emerging Regulatory Considerations
In 2025, both California and Oregon passed legislation intended to limit investor influence in physician practices, marking the beginning of a more active state-level regulatory environment.4
Physician-owners and buyers alike are monitoring these developments closely, as similar measures are under consideration in other states. Practices with transparent governance structures and documented compliance protocols are better positioned to navigate increasing regulatory scrutiny.
Scale Effect on Physician Practice Valuations
Larger groups with professional management and scalable infrastructure consistently attract higher multiples.
Scale translates directly into operational efficiency and reduced buyer risk. Practices with centralized office systems, established leadership, and documented compliance protocols demonstrate the infrastructure private equity firms seek in anchor investments.
| EBITDA Range | Typical Valuation Range (EV/EBITDA) | Example |
|---|---|---|
| <$1M | 5×–7× | Single-site or small group practice |
| $1M–$3M | 7×–9× | Mid-sized specialty group with modest ancillaries |
| $3M–$5M | 9×–11× | Larger practice with multi-site operations |
| >$5M | 11×–13× | Platform-ready organization with ASC or risk-based contracts |
Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Current market data confirms that practices generating $5M+ in EBITDA consistently command 10–12× multiples or higher, while smaller practices in the $500K–$1M EBITDA range typically see 6–8×. This scale premium reflects reduced execution risk and greater growth potential that institutional buyers value.3
Factors Influencing Multiples in Physician Practice M&A
Beyond financial metrics, qualitative elements such as physician retention, referral stability, and local market saturation have a meaningful impact on buyer perception. A group with younger physicians under long-term contracts, for example, may receive a 1–2x premium relative to a comparable group nearing retirement transition. These factors contribute to the larger multiple ranges discussed above.
| Valuation Driver | Potential Effect on Multiples | Rationale |
|---|---|---|
| Medical Specialty & Ancillaries | +2–4× premium | High-margin specialties and ancillary income streams boost value |
| Payor Mix & Reimbursement | ±1.5–2× | Greater commercial and self-pay mix improves margins and predictability. Commercial payers reimburse approximately 89% higher than Medicare on average.3 |
| Growth Potential | +1–3× | Expansion runway, new sites, or ancillary service additions signal scalability |
| Scale & Infrastructure | +2–4× | Larger, well-managed practices command higher multiples due to reduced risk |
| Geographic Density | +1–2× | Market dominance and referral control enhance negotiating leverage |
| Technology & AI Readiness | +0.5–1× | Practices with modern EHR, telehealth, and AI-enabled workflows increasingly command a technology premium from strategic buyers.2 |
Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Platform vs. Add-On Valuation Dynamics
Private equity firms employ a two-tiered valuation model, offering premium multiples for platforms and capturing arbitrage through add-on acquisitions.
By acquiring smaller practices at lower multiples and consolidating them into a larger network, PE investors create multiple arbitrage opportunities. The combined platform, once scaled and recapitalized, may ultimately trade at 12×–14× EBITDA or more upon exit.
| Transaction Type | Typical Buyer | Valuation Range (EV/EBITDA) | Strategic Focus |
|---|---|---|---|
| Platform Investment | Private equity sponsor, new specialty entry or large acquisition for an existing platform | 10×–15× | Management depth, scalability, and regional market entry |
| Add-On Acquisition | Existing PE-backed platform | 6×–9× | Integration fit, new geography, or ancillary enhancement |
How Buyers Underwrite Growth
When evaluating physician practice transactions, private equity sponsors model EBITDA expansion over a five- to seven-year hold period. Typical underwriting assumes l EBITDA growth through a mix of organic expansion, new site openings, and integration of ancillary services.
Investors also anticipate synergy gains from shared back-office functions, including revenue cycle, HR, supply purchasing, and IT. Platform buyers frequently invest in leadership recruitment, analytics, and marketing infrastructure early in the hold to accelerate scalability.
The convergence of healthcare services and technology is also reshaping how buyers underwrite growth. Acquirers are increasingly targeting practices with software-enabled clinical workflows, AI-assisted diagnostics, and telehealth capabilities, recognizing that technology integration drives both operational efficiency and higher exit multiples.2
Groups that can demonstrate a clear, data-supported growth plan, particularly one tied to regional expansion or value-based care contracts, often command the strongest valuations. Conversely, practices with limited growth visibility or physician turnover risk often see downward adjustments in buyer offers.
How Private Equity Evaluates Physician Practices
Private equity remains the dominant buyer in physician practice M&A, representing more than 90% of transactions. In 2025, private equity firms executed at least 1,029 tracked healthcare deals in the U.S., with outpatient care ranking as the third-busiest subsector by deal volume.4
Buyers assess:
Specialty attractiveness: Long-term demand, procedure growth, and reimbursement stability.
Payor diversification: Greater commercial and value-based participation reduces revenue risk.
Infrastructure maturity: Well-developed management and EHR systems enable rapid scaling.
Growth trajectory: Expansion potential within and beyond current geographies.
Technology readiness: AI integration and digital health capabilities are increasingly factored into buyer underwriting.2
Scarcity continues to drive heightened interest in cardiology, gastroenterology, and orthopedics, while value-based primary care remains a rising area for investors seeking recurring revenue and payer partnerships. Regulatory developments at the state level, including new legislation in California and Oregon, are prompting buyers to conduct more rigorous compliance diligence prior to closing.4
How FOCUS Uses Data to Drive Outcomes
FOCUS monitors valuation trends using verified transaction data from its completed engagements and leading healthcare mergers and acquisitions (M&A) databases. This includes information such as deal size, buyer type, and EBITDA multiple ranges across U.S. physician practice transactions.
By analyzing these datasets alongside current private equity deal flow, FOCUS identifies real-time shifts in buyer appetite, reimbursement outlook, and specialty-specific demand. These insights inform the firm’s strategic guidance on market timing, buyer selection, and transaction structure, helping physician-owners make informed decisions based on the latest industry data.
Sources
Bain & Company. Healthcare Private Equity Market 2025: Resurgence and Record Growth. Global Healthcare Private Equity Report 2026.
PCE Investment Bankers. Healthcare Industry Report, Q2 2025. July 2025.
Sofer Advisors. Medical Practice Valuation Multiples 2025–2026: Complete Guide. December 2025.
Private Equity Stakeholder Project (PESP). Private Equity Healthcare Deals: 2025 in Review. February 2026.
Irving Levin Associates. Healthcare Services Acquisition Report (2025). Accessed at: levinassociates.com.
PitchBook and Capital IQ transaction databases (accessed 2025–2026, data on recent physician practice M&A deals).
